Department of Cardiology, Bakırcay University Cigli Training and Research Hospital, Izmir, Turkey.
Department of Cardiology, Katip Çelebi University Faculty of Medicine, Izmir, Turkey.
J Clin Lab Anal. 2021 Jun;35(6):e23795. doi: 10.1002/jcla.23795. Epub 2021 May 4.
We aimed to evaluate the utility of the preprocedural platelet-lymphocyte ratio (PLR) for predicting the no-reflow phenomenon after thrombus aspiration during percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI).
We retrospectively analyzed postprocedural thrombolysis in myocardial infarction (TIMI) flow grades and myocardial blush grades (MBG) of 247 patients who underwent a PCI procedure with thrombus aspiration.We divided these patients into two groups according to whether they had no-reflow (TIMI < 3, MBG < 2) or not (TIMI 3, MBG ≥ 2).
No-reflow developed in 43 (17%) patients.Preprocedural PLR was significantly higher in the no-reflow group (183.76 ± 56.65 vs 118.32 ± 50.42 p < 0.001).Independent predictors of no-reflow were as follows: higher preprocedural platelet-lymphocyte ratio (PLR) (OR = 1.018; 95% CI = 1.004, 1.033; p = 0.013),mean corpuscular volume (MCV) (OR = 1.118; 95% CI = 1.024, 1.220; p = 0.012) and SYNTAX Score-2 (OR = 1.073; 95% CI = 1.005, 1.146; p = 0.036). PLR of 144 had 79% sensitivity and 75% specificity for the prediction of no-reflow.
PLR is a reliable predictor for no-reflow in STEMI patients undergoing thrombus aspiration.
本研究旨在评估血小板-淋巴细胞比值（PLR）在预测 ST 段抬高型心肌梗死（STEMI）患者经皮冠状动脉介入治疗（PCI）血栓抽吸后无复流现象中的作用。
我们回顾性分析了 247 例行血栓抽吸 PCI 术患者的术后心肌梗死溶栓试验（TIMI）血流分级和心肌灌注分级（MBG）。根据是否存在无复流（TIMI＜3 级，MBG＜2 级）将这些患者分为两组。
无复流发生在 43 例（17%）患者中。无复流组患者的术前 PLR 明显较高（183.76±56.65 与 118.32±50.42，p＜0.001）。无复流的独立预测因素包括：较高的术前血小板-淋巴细胞比值（PLR）（OR=1.018；95%CI=1.004，1.033；p=0.013）、平均红细胞体积（MCV）（OR=1.118；95%CI=1.024，1.220；p=0.012）和 SYNTAX 评分-2（OR=1.073；95%CI=1.005，1.146；p=0.036）。PLR 为 144 时，对无复流的预测具有 79%的敏感性和 75%的特异性。
PLR 是预测 STEMI 患者经血栓抽吸后无复流的可靠指标。
